reported that CXCL9 inhibits tumor growth and drives anti-PD-L1 therapy in ovarian cancer (20) and that CXCL9 could be a potential biomarker of immune infiltration associated with favorable prognosis in estrogen receptor-negative breast cancer (21). Here, CXCL9 is linked to ovarian cancer.